Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
04/2005
04/05/2005US6875793 Once-a-day controlled release sulfonylurea formulation
04/05/2005US6875789 Pyrazole-derived kinase inhibitors and uses thereof
04/05/2005US6875788 Non-insulin dependent diabetes, antidiabetic agents, dietetics, antilipemic agents, anticholesterol agents, cardiovascular disorders
04/05/2005US6875780 Compounds that modulate PPAR activity and methods for their preparation
04/05/2005US6875779 Cyclooxygenase inhibitor
04/05/2005US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
04/05/2005US6875741 Insulin and IGF-1 receptor agonists and antagonists
04/05/2005US6875736 Methods for identifying RNA binding compounds
04/05/2005US6875570 Proteins and nucleic acids encoding same
04/05/2005US6875443 An alcohol with chain length from about c20-c36 including policosanol, are therapeutically useful materials with efficacy in lowering cholesterol, can be advantageously added to foods such as margarines and salad dressings
04/05/2005US6875428 Especially endcapped polyethylene glycols, polypropylene glycols or copolymers of them
04/05/2005CA2339621C 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
04/03/2005CA2480616A1 Specific markers for diabetes
03/2005
03/31/2005WO2005028515A1 Recombinant antibody against human insulin-like growth factor
03/31/2005WO2005028491A1 Epimeredi glycoside a, the formulation containing thereof and their preparation method
03/31/2005WO2005028476A1 Substituted indolizine 1,2,3,6,7,8 derivatives, fgfs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives
03/31/2005WO2005028464A1 Endurance improving agent
03/31/2005WO2005028455A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
03/31/2005WO2005028453A1 Phenylacetic acid derivative, process for producing the same, and use
03/31/2005WO2005028450A1 Polymorphic forms of a known antihyperlipemic agent
03/31/2005WO2005028438A1 Novel piperidine derivative
03/31/2005WO2005028426A1 Novel 4-phenylamino-benzaldoxime derivative and use thereof as mek inhibitor
03/31/2005WO2005027973A2 Combinations of a vegf receptor inhibitor with other therapeutic agents
03/31/2005WO2005027967A1 Medicinal composition
03/31/2005WO2005027952A1 Composition exerting physiological activity via biological immune mechanism
03/31/2005WO2005027931A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
03/31/2005WO2005027929A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
03/31/2005WO2005027928A1 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
03/31/2005WO2005027926A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bone morphogenetic protein
03/31/2005WO2005027924A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005WO2005027922A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause
03/31/2005WO2005027921A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
03/31/2005WO2005027920A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
03/31/2005WO2005027919A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
03/31/2005WO2005027918A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
03/31/2005WO2005027917A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
03/31/2005WO2005027916A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
03/31/2005WO2005027915A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/31/2005WO2005027914A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
03/31/2005WO2005027913A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
03/31/2005WO2005027899A1 Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage
03/31/2005WO2005027898A1 Amino acid compositions
03/31/2005WO2005027892A1 Early insulin secretion promoter
03/31/2005WO2005027891A1 Accelerator for initial insulin secretion
03/31/2005WO2005027661A1 Compositions for the treatment and prevention of diabetes mellitus
03/31/2005WO2005027656A1 Functional sweetener
03/31/2005WO2005002600A3 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus
03/31/2005WO2004113270A3 Propionic acid derivatives useful in the treatment of lipid disorders
03/31/2005WO2004099171A3 Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
03/31/2005WO2004096276A9 Sugar intake-ability enhancer
03/31/2005WO2004064742A3 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms
03/31/2005WO2003099215A3 Antisense modulation of glucocorticoid receptor expression
03/31/2005WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp
03/31/2005WO2003040329A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/31/2005WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/31/2005US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease
03/31/2005US20050070712 Pyrimidine derivatives as ghrelin receptor modulators
03/31/2005US20050070706 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070699 Nucleotide sequences coding low density lipoprotein receptor-related protein 5 for use as tools in diagnosis and treatment of osteoporosis; high bone mass and bone disorders
03/31/2005US20050070689 Nucleotide sequences coding transmembrane activator and CAML interactor (TACI) protein for use in treatment and prevention of autoimmune disorders
03/31/2005US20050070606 Pharmaceutical agent for mitochondrial disorders
03/31/2005US20050070605 Reacting an organophosphouus compound with metallized alkane; forming atorvastatin, lorastatin, pitavastatin, fluvastatin
03/31/2005US20050070594 Use of angiotensin II receptor antagonists
03/31/2005US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
03/31/2005US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
03/31/2005US20050070566 Imidazoquinoline derivatives
03/31/2005US20050070562 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
03/31/2005US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions
03/31/2005US20050070557 Use of pyrazolo(4,3-d)pyrimidine derivatives; for example, 5-(3-chloro-benzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
03/31/2005US20050070555 Aroyl pyridinones
03/31/2005US20050070553 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
03/31/2005US20050070549 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation
03/31/2005US20050070535 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070534 Non-peptidic NPY Y2 receptor inhibitors
03/31/2005US20050070532 Peroxisome proliferator activated receptors (PPARS); for inhibiting formation of adipocytes; for treatment of obesity, diabetes, hyperinsulinemia, and polycystic ovary syndrome
03/31/2005US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder
03/31/2005US20050070530 Dipeptidyl peptidase inhibitors
03/31/2005US20050070517 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
03/31/2005US20050070512 Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
03/31/2005US20050070502 Orally administering a starch in granulated form having a reduced surface available for enzymatic degradation, which releases reducing sugars at a controlled rate; for nocturnal hypoglycemia in diabetes patients, endurance athletes
03/31/2005US20050070498 Enteral formulation
03/31/2005US20050070485 Phenylalanine derivatives
03/31/2005US20050070482 Peptides substituted with a functional group that reacts with an active site residue of the targeted protease, e.g., Cyclohexylglycine BoroAla, and compounds that can hydrolyzed to produce them; improved specificity for regulating glucose metabolism
03/31/2005US20050070481 By adding an antioxidant and/or a chelating agent in the same aqueous solution; reduced coenzyme Q10, vitamin C and ethylenediaminetetracetic acid for example
03/31/2005US20050070469 oxyntomodulin a polypeptide is administered to a obese mammal by oral, parenteral, mucosal, rectal subcutaneous or transdermal administration
03/31/2005US20050070459 treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor
03/31/2005US20050069971 Identifying modulators of transmembrane protein (PROLIXIN) for use in prevention and treatment of hyperlipidemia, athersclerosis, insulin resistance, diabetes and hypertension
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069876 Polypeptide for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, cardiovascular, neurological and developmental disorders.
03/31/2005US20050069598 Antidiabetic agents; moderate glucagon-like peptide; phosphoenolpyruvate carboxykinase inhbitors; weight control
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069559 Lawsonia intracellularis vaccine
03/31/2005US20050069537 Stimulants of survival of cells; binding of cellular adhesion molecular; prevent apoptosis
03/31/2005US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
03/31/2005US20050069492 As neuroprotective agents in the therapy of neuronal disorders of the central and peripheral nervous systems
03/31/2005DE10331202A1 Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms Use of whey permeate for the treatment of metabolic syndrome
03/31/2005CA2551037A1 Novel piperidine derivative
03/31/2005CA2540138A1 Recombinant antibody against human insulin-like growth factor
1 ... 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 ... 1298